In short
Clinical trials are investigating LTI-03 in people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. The study aims to assess safety, tolerability, and early signs of benefit in adults with IPF, including some who may already be on standard antifibrotic treatment.
Key points
- LTI-03 is being studied in a Phase 2 clinical trial for idiopathic pulmonary fibrosis, also called IPF. The trial looks at safety, tolerability, and early efficacy signals in adults with IPF diagnosed within the past 5 years. Some participants may already be receiving standard antifibrotic therapy. The study compares inhaled LTI-03 with a placebo. The main outcome is the number of treatment-emergent adverse events from Day 1 through Week 24.
Trial overview
The available clinical trial for LTI-03 is called RENEW and is a Phase 2 study in people with idiopathic pulmonary fibrosis (IPF). It is an interventional study, which means researchers give a study treatment and then measure what happens. The trial is authorised and plans to enroll 120 participants.
Who can join the study
This study is for patients with IPF who were diagnosed within 5 years before screening. The brief summary also says that some participants may already be receiving standard of care antifibrotic therapy, meaning their usual treatment for lung scarring may continue while they take part in the study.
What is being measured
The main endpoint, or main result the study wants to measure, is the incidence of treatment-emergent adverse events (TEAEs) from Day 1 through Week 24. TEAEs are medical problems that start after treatment begins or get worse during the study. The trial title also says it will look at safety, tolerability, and efficacy, so the researchers want to know whether the treatment is safe, how well people can take it, and whether it shows signs of helping IPF.
Study design and treatment groups
The study compares inhaled LTI-03 with a placebo. The trial description lists the study drug as LTI-03 10 mg by inhalation and the placebo as InhaLac® 500, which is micronized lactose monohydrate. A placebo is a look-alike treatment used for comparison, so researchers can better understand the effect of the study drug.
What the phase means
Phase 2 trials are usually done after early safety testing and are meant to learn more about how a treatment performs in a specific patient group. In this study, the focus is on people with IPF, so the results may help show whether LTI-03 deserves further study in this disease.
Key patient terms
- Idiopathic pulmonary fibrosis (IPF) means long-term scarring of the lungs, and the cause is not known.
- Screening is the check done before joining a trial to see if a person meets the study rules.
- Enrollment is the number of people the study plans to include, which is 120 in this trial.
- Safety means looking for unwanted medical problems during the study.
- Tolerability means how well participants can take the treatment without too much trouble.